1. Hosseini, Parastoo, Rahimi Foroushani, Abbas, Marjani, Arezoo, Mozhgani, Sayed-Hamidreza, Norouzi, Mehdi. . Investigating the effect of MAP2K1 gene (MEK1) in MAPK pathway in the induction of adult T-cell leukemia/lymphoma (ATLL). In Iranian journal of microbiology, 15, 475-481. doi:10.18502/ijm.v15i3.12910. https://pubmed.ncbi.nlm.nih.gov/37448673/
2. Ye, Ting, Zhang, Jie-Ying, Liu, Xin-Yi, Ye, Cheng-Zhi, Chen, Jing. 2022. The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. In Frontiers in immunology, 12, 785526. doi:10.3389/fimmu.2021.785526. https://pubmed.ncbi.nlm.nih.gov/35069558/
3. Sudduth, Christopher L, Smits, Patrick J, Vivero, Matthew P, Warman, Matthew L, Greene, Arin K. 2023. Arteriovenous malformation Map2k1 mutation affects vasculogenesis. In Scientific reports, 13, 11074. doi:10.1038/s41598-023-35301-6. https://pubmed.ncbi.nlm.nih.gov/37422456/
4. Alomari, Ahmed K, Harms, Paul W, Andea, Aleodor A, Warren, Simon J. 2023. MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations. In Journal of cutaneous pathology, 50, 1083-1093. doi:10.1111/cup.14502. https://pubmed.ncbi.nlm.nih.gov/37565534/